Search results for "First line"

showing 10 items of 83 documents

Oral Rhabdomyosarcoma: a review

2012

Rhabdomyosarcoma (RMS) is a rare malignant soft tissue neoplasm comprised of cells derived from the primitive mesen¬chyme. About 35% of RMS arises in the head and neck, are are classified as parameningeal and non-parameningeal forms. These are the most common soft tissue sarcoma of the children, adolescents and young adults. Their etiopathogenesis and its molecular relevance have been emphasized. The first line of treatment is radical excision and this is usually supplemented by radiotherapy. It is believed that adjunct combination chemotherapy may greatly improve the prognosis. Inadequately treated tumours grow in an infiltrative manner and recur in a high percentage of cases. Bone does no…

Pathologymedicine.medical_specialtyOral Medicine and Pathologybusiness.industryFirst linemedicine.medical_treatmentSoft tissue sarcomaCombination chemotherapyMalignant Soft Tissue NeoplasmParameningealOdontologíaReviewmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludRadiation therapyUNESCO::CIENCIAS MÉDICASMedicinebusinessHead and neckRhabdomyosarcomaGeneral Dentistry
researchProduct

Levetiracetam in Neonatal Seizures as First-line Treatment: A Prospective Study

2017

Aim of the Study: The aim of this study is to evaluate the efficacy and safety of levetiracetam (LEV) as first-line treatment of neonatal seizures. Materials and Methods: This study was conducted in patients of Neonatal Intensive Care Unit of Santo Bambino Hospital, University of Catania, Italy, from January to August 2016. A total of 16 neonates with convulsions not associated with major syndromes, which required anticonvulsant therapy, were included and underwent IV LEV at standard doses. Results: All patients responded to treatment, with a variety range of seizure resolution period (from 24 h to 15 days; mean hours: 96 ± 110.95). No patient required a second anticonvulsant therapy. Regar…

Pediatricsmedicine.medical_specialtyEfficiency and safety; levetiracetam; neonatal seizures; prospective studyNeonatal intensive care unitlevetiracetamneonatal seizuresAnticonvulsant therapyNO03 medical and health sciences0302 clinical medicine030225 pediatricsMedicineIn patientProspective cohort studybusiness.industryGeneral NeuroscienceEfficiency and safetyFirst line treatmentEfficiency and safety; levetiracetam; neonatal seizures; prospective study;AnesthesiaPediatrics Perinatology and Child HealthOriginal Articleneonatal seizureLevetiracetambusiness030217 neurology & neurosurgerymedicine.drugprospective study
researchProduct

EAACI/GA²LEN/EDF/WAO guideline: management of urticaria

2009

This guideline, together with its sister guideline on the classification of urticaria (Zuberbier T, Asero R, Bindslev-Jensen C, Canonica GW, Church MK, Gimenez-Arnau AM et al. EAACI/GA(2)LEN/EDF/WAO Guideline: definition, classification and diagnosis of urticaria. Allergy 2009;64: 1417-1426), is the result of a consensus reached during a panel discussion at the Third International Consensus Meeting on Urticaria, Urticaria 2008, a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF) and the World Al…

Pediatricsmedicine.medical_specialtybusiness.industryImmunologyMEDLINEGuidelinemedicine.diseaseFirst line treatmentQuality of lifeFamily medicinemedicineImmunology and Allergymedia_common.cataloged_instanceEffective treatmentPhysical urticariaEuropean unionbusinessPanel discussionmedia_commonAllergy
researchProduct

Should continuous infusion of β‐lactam antibiotics be the first‐line approach?

1997

PharmacologyContinuous infusionbusiness.industryStaphylococcusFirst lineStreptococcusMicrobial Sensitivity TestsPharmacologyGram-Positive Bacteriabeta-LactamsAnti-Bacterial AgentsDrug Delivery SystemsInjections IntravenousAnimalsHumansMedicinePharmacology (medical)Infusions IntravenousbusinessEnterococcusGram-Positive Bacterial InfectionsBeta lactam antibioticsJournal of Clinical Pharmacy and Therapeutics
researchProduct

Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)

2019

Abstract Background Elevated LDH is a known predictive and prognostic factor correlating with poor response rates and survival in patients (pts) with metastatic melanoma (MM) treated with targeted therapy (BRAF plus MEK inhibitors, TT) or immune checkpoint inhibitors (ICI). Whether TT or ICI in this subgroup of pts is more beneficial is unknown. Methods Pts with MM and elevated LDH who started first-line therapy between March 2016 and June 2017 were retrospectively identified from 25 melanoma centers. The cohort was divided into 2 groups: pts receiving TT first-line (TT group) and ICI first-line (ICI group). Primary endpoints were overall response rate (ORR), progression-free survival (PFS)…

Prognostic factormedicine.medical_specialtyMetastatic melanomabusiness.industryFirst lineImmune checkpoint inhibitorsHematologyOncologyFamily medicineOverall survivalMedicineDisease characteristicsIn patientElevated ldhbusiness
researchProduct

P33.15 TMB in the First-Line Setting of NSCLC: A Systematic Review with Indirect Comparisons Between PD-1 and PD-L1 Inhibitors

2021

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyOncologybiologybusiness.industryPD-L1First lineInternal medicinemedicinebiology.proteinbusinessJournal of Thoracic Oncology
researchProduct

189TiP Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutat…

2021

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industryAfatinibPhase IV TrialFirst line treatmentOncologyEgfr mutationInternal medicinemedicineOsimertinibIn patientbusinessmedicine.drugJournal of Thoracic Oncology
researchProduct

Impact of prognostic factors on long-term outcomes in metastatic breast cancer (MBC) patients (pts) receiving bevacizumab (B) plus paclitaxel as firs…

2014

e12007 Background: B combined with chemotherapy (CT) significantly improves progression-free survival (PFS) and response rate (RR) vs CT alone in the first-line treatment of HER2-negative MBC. In a...

Response rate (survey)OncologyCancer Researchmedicine.medical_specialtyChemotherapyBevacizumabbusiness.industryFirst linemedicine.medical_treatmentMedizinmedicine.diseaseMetastatic breast cancerSurgerychemistry.chemical_compoundOncologyPaclitaxelchemistryInternal medicinemedicineLong term outcomesCytotoxic T cellskin and connective tissue diseasesbusinessneoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct

Ultrasound as first line step in anaemia diagnostics

2019

This review covers the role of ultrasonography as an essential non-invasive diagnostic approach when facing patients with anemia, a common clinical problem. Abdomen ultrasound is well recognized as a first-line examination in the setting of blood loss, both acute and chronic. Less is clear about the additional opportunities, given by ultrasound in anemia, due to the many other possible causes.
 Here we provide information on the utility of ultrasound in different contexts and a practical guide for clinicians facing anemic patients

medicine.medical_specialtySettore MED/09 - Medicina Internalcsh:RC633-647.5business.industryFirst lineUltrasoundAnaemiaReview Articlelcsh:Diseases of the blood and blood-forming organsHematology030204 cardiovascular system & hematologyAbdomen ultrasound03 medical and health sciences0302 clinical medicineInfectious DiseasesBlood lossanaemia; ultrasoundUltrasoundmedicine030211 gastroenterology & hepatologyRadiologyUltrasonographybusiness
researchProduct

Could isotretinoin be a protective agent against COVID-19?: A dermatologist perspective.

2021

Being a "trending" unique treatment for moderate-to-severe acne, isotretinoin (13-cis retinoic acid) (ISO) is currently considered by experts the first line treatment even for mild acne, unless there is an absolute contraindication. ISO was identified, among other retinoids, to inhibit SARS-CoV-2 replication in Vero E6 cells. Shoemark et al.1.

medicine.medical_specialtyskinCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Retinoic acidDermatologyProtective Agents030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCOVID‐19Acne VulgarismedicineHumansskin and connective tissue diseasesLetters to the EditorIsotretinoinContraindicationAcnebusiness.industrySARS-CoV-2COVID-19isotretinoinmedicine.diseaseDermatologyFirst line treatmentchemistry030220 oncology & carcinogenesisVero cellbusinessmedicine.drugDermatologistsJournal of cosmetic dermatology
researchProduct